This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Educational information

The educational objectives of this symposum were to:

• Discuss the potential of current and future strategies targeting inflammation in reducing residual risk in post ACS patients
• Outline current ongoing clinical development programs aimed at testing the inflammation hypothesis of cardiovascular disease
• Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients post ACS
• Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
• To review the clinical significance of additional lipid lowering pathways, such as ezetimibe, in the management of patients with ACS
• Understand the implications of new guidelines for lipid management

Faculty

Paul M Ridker, MD, MPH: Eugene Braunwald Professor of Medicine, Harvard Medical School, Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, Massachusetts

Disclosures

This EBAC accredited symposium was funded by an unrestricted educational grants received from Novartis, MSD, Amgen

Also watch lecture: Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies by prof Erik Stroes, MD – AMC, Amsterdam, The Netherlands Also watch lecture: Beyond statins: The role of ezetimibe in targeting residual risk - by prof Chris Packard, MD, University of Glasgow, United Kingdom